Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Accumulated Expenses (2021 - 2025)

Lyra Therapeutics (LYRA) has disclosed Accumulated Expenses for 5 consecutive years, with $3.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Accumulated Expenses fell 4.32% to $3.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $3.1 million, a 4.32% decrease, with the full-year FY2024 number at $4.3 million, down 6.92% from a year prior.
  • Accumulated Expenses was $3.1 million for Q3 2025 at Lyra Therapeutics, up from $2.4 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $11.1 million in Q3 2023 to a low of $1.5 million in Q1 2022.
  • A 5-year average of $4.4 million and a median of $3.1 million in 2024 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: surged 343.12% in 2023, then crashed 77.66% in 2025.
  • Lyra Therapeutics' Accumulated Expenses stood at $2.4 million in 2021, then increased by 22.48% to $3.0 million in 2022, then skyrocketed by 56.97% to $4.7 million in 2023, then dropped by 6.92% to $4.3 million in 2024, then dropped by 29.63% to $3.1 million in 2025.
  • Per Business Quant, the three most recent readings for LYRA's Accumulated Expenses are $3.1 million (Q3 2025), $2.4 million (Q2 2025), and $2.2 million (Q1 2025).